

```
var drug_url = "glecaprevir-pibrentasvir";
```



Glecaprevir-Pibrentasvir (*Mavyret*)

Other Names: **GLE-PIB**

- [Editor's Summary](#)
- [Prescribing Information](#)
- [Clinical Trials](#)
- [References](#)
- [Slide Deck](#)
- [Teaching Resources](#)

Table of Contents

- [Glecaprevir-Pibrentasvir *Mavyret* Editor's Summary](#)
- [Drug Summary](#)
- [Class and Mechanism](#)
- [Manufacturer for United States](#)
- [Cost and Medication Access](#)
- [Adverse Effects](#)
- [Key Drug Interactions](#)

Drug Summary

Glecaprevir-pibrentasvir is the first pangenotypic NS3/4A protease inhibitor-NS5A inhibitor combination to be approved that offers a potent ribavirin-free option for the vast majority of patients with chronic hepatitis C, including a potential 8-week option for non-cirrhotic patients with renal disease or HIV coinfection. This drug is not an option for patients with decompensated cirrhosis (Child B/C) given the presence of the protease inhibitor. In main registration trials, sustained virologic response rates for 8 or 12 weeks of glecaprevir-pibrentasvir for genotypes 1, 2, 5 or 6 were in the range of 98-100% with very few if any on-treatment virologic breakthroughs or post-treatment relapses. Despite earning an 8-week FDA indication for all genotypes (treatment-naïve) without cirrhosis, the efficacy of 8 weeks of glecaprevir-pibrentasvir was numerically lower for genotype 3 and 4 at 95% and 93% respectively. Glecaprevir-pibrentasvir is by far the least expensive of all DAAs, priced at \$26,400 for an 8-week course (less than half the wholesale acquisition cost of 8 weeks of ledipasvir-sofosbuvir), and it is anticipated to expand and transform the treatment landscape worldwide.

Class and Mechanism

Glecaprevir (GLE, formerly ABT-493) is an NS3/4A protease inhibitor that prevents the cleavage of the HCV polyprotein. It has potent in vitro activity (on the order of less than or equal to 5 nanomolar), across the HCV genotypes including common HCV genotype 1 variants that have substitutions (at Q80, R155 and D168) conferring resistance to older-generation HCV protease inhibitors. Pibrentasvir (PIB, formerly ABT-530) is a next-generation NS5A inhibitor with pangenotypic activity in vitro; it maintains potent antiviral activity against common HCV NS5A single-position variants that confer resistance to first-generation NS5A inhibitors, including daclatasvir, ledipasvir, and ombitasvir.

Manufacturer for United States

The fixed dose medication glecaprevir-pibrentasvir (*Mavyret*) ([Figure 1](#)) is manufactured by AbbVie Inc. Each fixed-dose tablet contains 100 mg of glecaprevir and 40 mg of pibrentasvir ([Figure 2](#)).

Cost and Medication Access

The wholesale acquisition cost (WAC) for a 8-week course of glecaprevir-pibrentasvir is \$26,400. The 8-week course of glecaprevir-pibrentasvir is indicated for treatment-naïve noncirrhotic patients with genotypes 1-6 HCV; this 8-week treatment course makes glecaprevir-pibrentasvir by far the least expensive option among all of the recommended treatment options for non-cirrhotic treatment-naïve patients. The 12-week treatment course has a cost of \$39,600 and this duration is indicated for treatment-naïve patients with compensated cirrhosis (Child-Pugh A) and some treatment experienced patients. The 16-week treatment course is \$52,800 and is indicated for some subsets of treatment-experienced patients.

Adverse Effects

The most common adverse effects, observed in at least 10% of phase 3 trial participants, were headache and fatigue.

Key Drug Interactions

For complete information on glecaprevir-pibrentasvir-related drug interactions, see the [Drug Interactions section in the Glecaprevir-Pibrentasvir \(*Mavyret*\) Prescribing Information](#).

Clinical Trials

Filter by Category

- All Clinical Trials
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Pharmacology
- Pharmacology
- Pharmacology

ENDURANCE-1

In this phase 3 open-label trial, 703 noncirrhotic adults with genotype 1 HCV infection were randomized to receive either 8 or 12 weeks of glecaprevir-pibrentasvir; 38% were treatment-experienced (3 were sofosbuvir experienced and the remainder interferon experienced). Among those enrolled 33 were coinfecting with HIV. The sustained virologic response rate (SVR12) was 99% for the 8-week arm and 99.7% for the 12-week arm, and the SVR rate remained high in persons with

HIV coinfection, prior treatment experience, and baseline resistance-associated substitutions.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

ENDURANCE-2

This phase 3 randomized, double-blind placebo-controlled trial evaluated the safety and efficacy of 12 weeks of therapy with glecaprevir-pibrentasvir in patients with genotype 2 hepatitis C infection without cirrhosis. Thirty percent were treatment-experienced; most (91%) had received interferon-based while the remainder sofosbuvir-based therapy. Among DAA-naive patients who received glecaprevir-pibrentasvir, 195 (99%) of 196 achieved a sustained virologic response 12 (SVR12) by intent-to-treat analysis. There were no serious adverse events related to glecaprevir-pibrentasvir.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

ENDURANCE-3

In this phase 3 randomized study, investigators compared the efficacy and safety of 8 or 12 weeks of glecaprevir-pibrentasvir versus 12 weeks of sofosbuvir and daclatasvir in non-cirrhotic treatment-naive adults with genotype 3 hepatitis C infection; 348 patients were randomized in 2:1 ratio to 12 weeks of either glecaprevir-pibrentasvir or sofosbuvir plus daclatasvir while 157 were assigned to 8 weeks of glecaprevir-pibrentasvir. Sustained virologic response (SVR12) was achieved in 95% of patients in both the 8-week and 12-week glecaprevir-pibrentasvir arms by intent-to-treat analysis. The 12-week glecaprevir-pibrentasvir arm met non-inferiority criteria for SVR12 when compared with sofosbuvir plus daclatasvir. Glecaprevir-pibrentasvir was well tolerated with a low incidence (2%) of any serious adverse reactions.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

ENDURANCE-4

In this single-arm trial, 121 non-cirrhotic adults with genotype 4, 5 or 6 infection were assigned to 12 weeks of glecaprevir-pibrentasvir. Most of these patients (68%) were treatment-naive; 39% had prior interferon-based therapy. Nearly all (99%) achieved a sustained virologic response; the only individual who did not achieve SRV12 discontinued therapy after only 12 days.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

EXPEDITION-1

This phase 3 single-arm open-label trial evaluated the safety and efficacy of 12 weeks of glecaprevir-pibrentasvir in 146 adults with compensated cirrhosis and genotype 1, 2, 4, 5, or 6 hepatitis C infection. Sixty percent were genotype 1 patients; 25% were treatment-experienced—most (69%) had previously received interferon-based treatment and the remainder had received sofosbuvir-based therapy. The overall sustained virologic response rate was 99%; one patient with genotype 1a experienced a viral relapse at week 8 post-treatment, and had Y93N substitution detected at baseline and at time of failure.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

EXPEDITION-2

In this open-label, dual-arm phase 3 trial, 137 noncirrhotic adults with HCV (genotype 1-6) and HIV coinfection were assigned 8 weeks of glecaprevir-pibrentasvir and 16 coinfecting patients with compensated cirrhosis received 12 weeks of glecaprevir-pibrentasvir. The majority (63%) of participants had genotype 1 infection; 18% were treatment-experienced (16% with interferon and 2% were sofosbuvir based). All but 10 patients were taking either raltegravir, dolutegravir or rilpivirine as the anchor drug for antiretroviral therapy. The overall sustained virologic response rate was 98%; one patient with genotype 3 with cirrhosis experienced on-treatment virologic breakthrough.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

EXPEDITION-4

This phase 3 single-arm open-label trial evaluated the safety and efficacy of 12 weeks of glecaprevir-pibrentasvir in 104 patients with genotype 1-6 hepatitis C infection and advanced renal insufficiency (estimated glomerular filtration rate less than 30 ml/min/1.73m²); 88% had chronic kidney disease stage 5 and 82% were on hemodialysis. Fifty-two percent of patients had genotype 1 infection; 19% had compensated cirrhosis and 42% were treatment-experienced, all but two with prior interferon-based therapy. The overall sustained virologic response rate was 98% by intent-to-treat analysis. The rate of adverse events attributable to glecaprevir-pibrentasvir (pruritus 20%, fatigue 14%, nausea 12%) were comparable to those observed in the other glecaprevir-pibrentasvir trials.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

MAGELLAN-1 (Part 1)

In this phase 2 open-label trial, 50 genotype 1 patients without cirrhosis who had previously failed a DAA-containing regimen were randomized to 3 arms: (A) glecaprevir-pibrentasvir (GLE-PIB) 200-80 mg daily, (B) GLE-PIB 300/120 mg with ribavirin 800 mg daily and (C) GLE-PIB 200/120 mg daily - all for 12 weeks. By intent-to-treat analysis, a sustained virologic response (SVR12) was achieved in 100% (6/6) of patients in arm A, 95% (21/22) of patients in arm B and 86% (19/22) of patients in arm C. SVR12 was achieved in 91% (10/11) and 93% (14/15) of patients with baseline resistance-associated substitutions (RAS) to NS5A only and both NS3 and NS5A respectively, to a 15% detection threshold. All patients without baseline RAS or with only NS3 RAS achieved an SVR12.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

SURVEYOR-I and SURVEYOR-II

SURVEYOR-1 (for genotypes 1, 4, 5 and 6) and SURVEYOR-2 (genotypes 2 and 3) were both phase 2 open-label trials of non-cirrhotic patients. Part 1 of each study evaluated the efficacy of various doses of glecaprevir-pibrentasvir (GLE-PIB) for 12 weeks and Part 2 examined the optimized dose of 300/120 mg for 8 versus 12 weeks. The dose-ranging studies (Part 1) confirmed that 300/120 mg of

GLE-PIB had high efficacy across the genotypes (96-100%) and that the addition of ribavirin in genotype 2 or 3 did not appear to be associated with any difference in response. In Part 2, there were no virologic failures among the 203 treatment-naïve patients who received either 8 or 12 weeks of GLE-PIB 300/120 mg. There were however two relapses and one breakthrough among the 27 patients with genotype 3 who were peginterferon and ribavirin-experienced.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

References

- Asselah T, Hezode C, Zadeikis N, et al. ENDURANCE-4: efficacy and safety of Glecaprevir/Pibrentasvir (Formerly ABT-493/ABT-530) treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Programs and abstracts of the 2016 AASLD Meeting; November 11-15, 2016; Boston, Massachusetts. Abstract 114.
- Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. *Lancet Infect Dis*. 2017 Aug 14.[Epub ahead of print]
[[PubMed Abstract](#)]
- Foster GR., Gane E, Asatryan A, et al. ENDURANCE-3: a phase 3, randomized, open-label, active-controlled study to compare efficacy and safety of ABT-493/ABT-530 to Sofosbuvir co-administered with Daclatasvir in adults with HCV genotype 3 infection. Program and abstracts of 2017 European Association for the Study of the Liver annual meeting; April 19-23, 2017; Amsterdam, The Netherlands. Abstract GS-007.
- Gane E, Lawitz E, Pugatch D, et al. EXPEDITION-4: efficacy and safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection. Programs and abstracts of the 2016 AASLD Meeting; November 11-15, 2016; Boston, Massachusetts. Abstract LB11.
- Gane E, Poordad F, Wang S, et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. *Gastroenterology*. 2016;151:651-9.e1.
[[PubMed Abstract](#)]
- Kowdley KV, Colombo M, Zadeikis N, et al. ENDURANCE-2: safety and efficacy of Glecaprevir/Pibrentasvir in hepatitis C virus genotype 2-infected patients without cirrhosis: a randomized, double-blind, placebo-controlled study. Programs and abstracts of the 2016 AASLD Meeting; November 11-15, 2016; Boston, Massachusetts. Abstract 73.
- Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. *J Hepatol*. 2017;67:263-271.
[[PubMed Abstract](#)]
- Lawitz EJ, O'Riordan WD, Asatryan A, et al. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. *Antimicrob Agents Chemother*. 2015;60:1546-55.
[[PubMed Abstract](#)]
- Lin CW, Dutta S, Asatryan A, et al. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. *J Pharm Sci*. 2017;106:645-651.
[[PubMed Abstract](#)]
- Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. *Eur J Drug Metab Pharmacokinet*. 2017 Jul 7. [Epub ahead of print]
[[PubMed Abstract](#)]
- Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. *Eur J Drug Metab Pharmacokinet*. 2017 Jul 7.[Epub ahead of print]
[[PubMed Abstract](#)]
- Ng TI, Krishnan P, Pilot-Matias T, et al. *In Vitro* Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. *Antimicrob Agents Chemother*. 2017;61.[Epub ahead of print]
[[PubMed Abstract](#)]
- Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. *Hepatology*. 2017;66:389-97.
[[PubMed Abstract](#)]
- Rockstroh J, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in

- patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Program and abstracts of the 9th International AIDS Society Conference on HIV Science, 2017; Paris. Abstract 918.
- Zeuzem S, Feld JJ, Wang S, et al. ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with Glecaprevir/Pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. Programs and abstracts of the 2016 AASLD Meeting; November 11-15, 2016; Boston, Massachusetts. Abstract 253.

Figures

Figure 1 Glecaprevir-Pibrentasvir (Mavyret) Packaging

Note each daily packet contains 3 glecaprevir-pibrenatasvir fixed-dose tablets and each tablet consists of 100 mg of glecaprevir and 40 mg of pibrentasvir.

This photograph is courtesy of AbbVie



Figure 2 Fixed-Dose Tablet of Glecaprevir-Pibrentasvir (Mavyret)

Each fixed dose tablet contains contains 100 mg of glecaprevir and 40 mg of pibrentasvir. The recommended daily dose is 3 tablets once daily.

Photo: Andrew Karpenko, University of Washington

